Overview

Phase II Study With ITF2984 in Acromegalic Patients

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate in acromegalic patients the effect of different doses of ITF2984 on GH and IGF-1 concentrations and to investigate safety and tolerability of three different doses of ITF2984.
Phase:
Phase 2
Details
Lead Sponsor:
Italfarmaco
Treatments:
Octreotide
Somatostatin